Datopotamab Deruxtecan Improves Survival Over Chemotherapy in Patients with Previously Untreated, Locally Recurrent Inoperable or Metastatic TNBC By Ogkologos - April 28, 2026 137 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPION-Breast02 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR FDA Grants Accelerated Approval to Talquetamab-tgvs for Relapsed or Refractory Multiple... September 15, 2023 “White Bagging” Harmful to Patients, Requires Them to Use Insurance-Approved Formulary... July 2, 2021 EMA Recommends Extension of Therapeutic Indications for Cabozantinib and Nivolumab March 4, 2021 Are New Immune-Based Treatments for Kidney and Pancreatic Cancer on the... April 23, 2025 Load more HOT NEWS Tattoo Artist Offers Free Nipple Tattoos To Breast Cancer Patients That... Patient Guide in Bladder Cancer Now Available Also in Italian Breaking down changes in NHS cancer waiting times in England 5th Grader Follows His Gut By Calling 911 On School Bus...
